BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Sempere A, Hurtado I, Bejarano-Quisoboni D, Rodríguez-Bernal C, Santa-Ana Y, Peiró S, Sanfélix-Gimeno G. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS One 2019;14:e0211681. [PMID: 30753227 DOI: 10.1371/journal.pone.0211681] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Barrios V, Cinza-Sanjurjo S, Gavín O, Egocheaga I, Burgos-Pol R, Soto J, Polanco C, Suárez J, Casado MÁ. Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed) 2021;74:773-80. [PMID: 32980294 DOI: 10.1016/j.rec.2020.06.033] [Reference Citation Analysis]
2 Chebrolu P, Patil S, Laux TS, Al-Hammadi N, Jain Y, Gage B. Quality of anticoagulation with warfarin in rural Chhattisgarh, India. Indian J Med Res 2020;152:303-7. [PMID: 33107491 DOI: 10.4103/ijmr.IJMR_1201_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Choi EK, Lee YS, Chern AKC, Jiampo P, Chutinet A, Hanafy DA, Trivedi P, Zhai D, Oh YS. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran. Open Heart 2020;7:e001343. [PMID: 33184127 DOI: 10.1136/openhrt-2020-001343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ferrari F, da Silveira AD, Martins VM, Franzoni LT, Zimerman LI, Stein R. Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. Cardiol Rev 2021;29:120-30. [PMID: 32332235 DOI: 10.1097/CRD.0000000000000312] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Barrios V, Cinza-sanjurjo S, Gavín O, Egocheaga I, Burgos-pol R, Soto J, Polanco C, Suárez J, Casado MÁ. Carga y coste del mal control de la anticoagulación con antagonistas de la vitamina K en pacientes con fibrilación auricular no valvular en España. Revista Española de Cardiología 2021;74:773-80. [DOI: 10.1016/j.recesp.2020.06.009] [Reference Citation Analysis]
6 Roldán Rabadán I, Esteve-Pastor MA, Anguita Sánchez M, Muñiz J, Ruiz Ortiz M, Marín F, Roldán V, Quesada MA, Camacho Siles J, Cequier Fillat A, Bertomeu Martinez V, Martínez Sellés M, Badimón L; FANTASIIA Study Investigators. Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study. Eur J Intern Med 2020;78:63-8. [PMID: 32303456 DOI: 10.1016/j.ejim.2020.04.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. PLoS One 2021;16:e0259251. [PMID: 34767564 DOI: 10.1371/journal.pone.0259251] [Reference Citation Analysis]
8 Iftimi AA, Rodríguez-Bernal CL, Peiró S, Bonanad S, Ferrero-Gregori A, Hurtado I, García-Sempere A, Sanfélix-Gimeno G. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients. Clin Pharmacol Ther 2021. [PMID: 34242404 DOI: 10.1002/cpt.2362] [Reference Citation Analysis]
9 Chen Q, Lapane K, Nunes AP, Tjia J, Hugunin J, Alcusky M. Prevalence and the factors associated with oral anticoagulant use among nursing home residents. J Clin Pharm Ther 2021. [PMID: 34463969 DOI: 10.1111/jcpt.13508] [Reference Citation Analysis]
10 Giner-Soriano M, Cortes J, Gomez-Lumbreras A, Prat-Vallverdú O, Quijada-Manuitt MA, Morros R. The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study. Aten Primaria 2020;52:529-38. [PMID: 32788057 DOI: 10.1016/j.aprim.2020.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Takamoto K, Sakamoto JI, Ito S, Kimura T, Manabe E, Shikata T, Asakura M, Ishihara M, Tsujino T. Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation. Front Pharmacol 2021;12:651799. [PMID: 33981231 DOI: 10.3389/fphar.2021.651799] [Reference Citation Analysis]
12 García-Sempere A, Orrico-Sánchez A, Muñoz-Quiles C, Hurtado I, Peiró S, Sanfélix-Gimeno G, Diez-Domingo J. Data Resource Profile: The Valencia Health System Integrated Database (VID). Int J Epidemiol 2020;49:740-741e. [PMID: 31977043 DOI: 10.1093/ije/dyz266] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
13 Dalmau Llorca MR, Aguilar Martín C, Carrasco-Querol N, Hernández Rojas Z, Forcadell Drago E, Rodríguez Cumplido D, Castro Blanco E, Gonçalves AQ, Fernández-Sáez J. Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). Int J Environ Res Public Health 2021;18:5700. [PMID: 34073370 DOI: 10.3390/ijerph18115700] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Varona JF, Seguí-Ripoll JM, Lozano-Duran C, Cuadrado-Gómez LM, Montagud-Moncho JB, Ramos-Guerrero A, Mirete-Ferrer JC, Donado E, García-Alegría J; REQUOL Study Group. Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status. Health Qual Life Outcomes 2020;18:383. [PMID: 33308246 DOI: 10.1186/s12955-020-01563-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]